IOBT

IO Biotech, Inc. [IOBT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IOBT Stock Summary

Top 10 Correlated ETFs

IOBT

Top 10 Correlated Stocks

IOBT

In the News

IOBT Financial details

Company Rating
-
Market Cap
102.12M
Income
-86.08M
Revenue
1.11M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
68
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.25
Forward P/E
-
PEG
0.94
P/S
-
P/B
0.63
P/C
-
P/FCF
-1.94
Quick Ratio
12.75
Current Ratio
12.96
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.15
EPS next Y
-
EPS next Q
-
EPS this Y
-20.16%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-6.98%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-46%
ROE
-61%
ROC
-0.52%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.816-2.64
52W High
-
52W Low
-
RSI
47
Rel Volume
0.67
Avg Volume
140.83K
Volume
94.44K
Perf Week
-4.76%
Perf Month
-7.22%
Perf Quarter
16.1%
Perf Half Y
6.64%
-
-
-
-
Beta
0.498
-
-
Volatility
0.02%, 0.06%
Prev Close
0%
Price
0.9
Change
-2.17%

Something similar

Top by Market Cap
V
META
APC.DE
GOOGL
LLY
Top Correlated ETFs
JJGTF
Top Correlated Stocks
TKN-R.BK
OBE.TO
NTLA
DVN
OXY
Similar Market Cap
WIRTEK.CO
LPTH
FOA
QIE.TO
THIRUSUGAR.NS

Company Profile

Healthcare Biotechnology
  • Volume Average 140.83K
  • Market Capitalization 102.12M
  • Employee 68
  • CEO Dr. Mai-Britt Zocca Ph.D.
  • Headquarters Copenhagen,DK
  • IPO Date 2021-11-05
  • Website https://www.iobiotech.com

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.